With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.
Around Town - Northeast Times northeasttimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from northeasttimes.com Daily Mail and Mail on Sunday newspapers.